Communicating Drug Quality Observations

Abstract

This paper describes the Food and Drug Administration's surveillance of the quality of prescription and nonprescription drug products distributed in the United States. It addresses a system to obtain voluntary reports, then evaluate and investigate reported observations. It also stresses the need to quickly communicate this information throughout the agency reviewing divisions, field investigation offices, and to the respective pharmaceutical firms to mitigate any potential public health hazards.